Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days (1999)

Author(s): Hughes, A. N., Rafi, I., Griffin, M. J., Calvert, A. H., Newell, D. R., Calvete, J., Johnston, A., Clendeninn, N., Boddy, A. V.

      • Journal: Clinical Cancer Research
      • Volume: 5
      • Issue: 1
      • Pages: 111-118
      • Publication type: Article
      • Bibliographic status: Published